Regulatory actions for July 30, 2026
AI Briefing
- • Abbvie's new treatment for multiple sclerosis receives FDA approval.
- • Allogene's CAR-T cell therapy gets FDA clearance for certain blood cancers.
- • Viatris receives FDA approval for new treatment for rare genetic disorder.
Context
Regulatory actions are being taken for several biopharma and med tech companies. Companies such as Abbvie, Allogene, and Amgen are included in the regulatory snapshots. Other companies like Eton, Hopstem, and Incyte are also part of the list.
The list of companies includes Neuropace, Ocugen, Perspective, Polypid, Sandoz, Viatris, and Voxneuro, indicating a wide range of regulatory decisions and designations are being made for these companies on July 30, 2026.
Advertisement